Global Health R&D Funding From Wealthy Nations Fell 6% In 2010, Annual G-FINDER Report Finds
“A group that tracks funding for neglected diseases released its fourth annual report Wednesday, showing for the first time since 2007 a decrease in government and public spending in global health research and development,” the Center for Global Health Policy’s “Science Speaks” blog reports (Mazzotta, 12/7). The Global Funding of Innovation for Neglected Diseases (G-FINDER) survey report, conducted by Policy Cures and funded by the Bill & Melinda Gates Foundation, found that “[p]ublic funding from the world’s richest nations for research and development (R&D) of new neglected disease products fell by US$125 million (down six percent) in 2010,” a Policy Cures press release (.pdf) states (12/7).
The decline “was partly offset by a 28 percent boost in funding from the not-for-profit programs of pharmaceutical companies,” Nature writes. “HIV research and development funding saw the greatest funding decrease, with a $70 million drop from the year before,” while tuberculosis (TB) was “one of the few areas to experience an increase in funding — a $30 million or six percent increase in 2010,” according to the magazine (Wadman, 12/7). Nature features a second article examining HIV funding details from the Policy Cures report (Wadman, 12/7).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.